Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group. Rousselot P, et al. Among authors: delord m. Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27. Cancer. 2017. PMID: 28026860 Free PMC article. Clinical Trial.
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC. Guilhot F, et al. Among authors: delord m. Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483613 Clinical Trial.
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group. Rousselot P, et al. Among authors: delord m. Blood. 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27. Blood. 2016. PMID: 27121472 Free PMC article.
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, Cony-Makhoul P, Coiteux V, Sutton L, Abarah W, Pouaty C, Pignon JM, Choufi B, Visanica S, Deau B, Morisset L, Cayssials E, Molimard M, Bouchet S, Mahon FX, Nicolini F, Aegerter P, Cayuela JM, Delord M, Bruzzoni-Giovanelli H, Rousselot P; Groupe Français pour la LMC (Fi-LMC). Johnson-Ansah H, et al. Among authors: delord m. Pharmaceutics. 2022 Aug 12;14(8):1676. doi: 10.3390/pharmaceutics14081676. Pharmaceutics. 2022. PMID: 36015302 Free PMC article.
PPARγ agonists promote the resolution of myelofibrosis in preclinical models.
Lambert J, Saliba J, Calderon C, Sii-Felice K, Salma M, Edmond V, Alvarez JC, Delord M, Marty C, Plo I, Kiladjian JJ, Soler E, Vainchenker W, Villeval JL, Rousselot P, Prost S. Lambert J, et al. Among authors: delord m. J Clin Invest. 2021 Jun 1;131(11):e136713. doi: 10.1172/JCI136713. J Clin Invest. 2021. PMID: 33914703 Free PMC article.
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
Kohn M, Delord M, Chbat M, Guemriche A, Merabet F, Roupie AL, Lombion N, Farhat H, Longval T, Cabannes-Hamy A, Lambert J, Marque-Juillet S, Raggueneau V, Osman J, Spentchian M, Rigaudeau S, Rousselot P, Besson C. Kohn M, et al. Among authors: delord m. Haematologica. 2022 Jun 1;107(6):1454-1459. doi: 10.3324/haematol.2021.280026. Haematologica. 2022. PMID: 34788987 Free PMC article. No abstract available.
106 results